Status:

COMPLETED

Natural History Study of Moles and Suspicious Melanoma

Lead Sponsor:

National Cancer Institute (NCI)

Conditions:

Melanocytic Nevi

Acquired Melanocytic Nevi

Eligibility:

All Genders

5+ years

Brief Summary

Background: * Melanocytic nevi, or "moles," are non-cancerous growths of a type of skin cell called a melanocyte. * Large congenital melanocytic nevi (LCMN) are a special type of mole that begins to ...

Detailed Description

The objective of this study is to understand early transformation and malignant progression events of cutaneous melanoma by obtaining detailed clinical information and lesional tissue for analysis, ce...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Infants/Children
  • Must be less than or equal to 5 years.
  • Must have large congenital melanocytic nevus (LCMN, diagnosed clinically or by biopsy) that is greater than 20 cm in any one dimension or that is greater than 8 cm in any one dimension involving the scalp.
  • Must have outside referring physician.
  • OR
  • Adults
  • Must be greater than 18 years.
  • Must have greater than or equal to 100 melanocytic nevi greater than 2 mm in diameter.
  • Must have at least one melanocytic nevus greater than or equal to 4 mm in longest dimension.
  • Can have prior history of cutaneous or ocular malignant melanoma.
  • Must have outside primary physician.
  • OR
  • Adults
  • Must be greater than 18 years.
  • Must have a current pigmented lesion clinically suspicious for primary melanoma.
  • Must have outside primary physician.
  • AND
  • All patients, or in the case of infants and children their parents or legal guardians, must be able to understand and sign an informed consent.
  • EXCLUSION CRITERIA:
  • The patient does not meet the inclusion criteria.
  • Diagnosis of genetic syndrome associated with multiple lentigines or nevi (Peutz-Jeghers syndrome, Carney complex, turner syndrome, Noonan's syndrome).
  • Two or more first-degree relatives with history of cutaneous melanoma and familial atypical mole-melanoma syndrome phenotype.
  • Diagnosis of cancer-associated syndrome (xeroderma pigmentosum, type I neurofibromatosis, Li-Fraumeni syndrome).
  • Inability to tolerate surgical procedure due to bleeding diathesis or disorder or other cause as determined by principal investigator.
  • Patient is unwilling to consider elective biopsy of a melanocytic nevus.

Exclusion

    Key Trial Info

    Start Date :

    February 3 2006

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    October 31 2011

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT00288938

    Start Date

    February 3 2006

    End Date

    October 31 2011

    Last Update

    July 2 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892